CD16 antibody and CD markers for receptors that also bind antibodies

Building a surface panel

1. Block Fc receptors before staining. Cells carrying Fc receptors bind antibodies through the constant region, producing signal in every channel. A blocking reagent appropriate to the species goes on before the panel, and its absence is the commonest cause of an uninterpretable myeloid stain.
2. Record the clone, not the cluster. A cluster designation names an antigen, not a reagent. Two clones can recognise different epitopes with different accessibility, and switching clone is a protocol change requiring re titration.
3. Titrate on your own cells. The optimal amount is the one giving the best separation between positive and negative populations on your sample, and it is usually below the datasheet dilution. One titration per clone pays for itself immediately.
4. Match fluorophore brightness to antigen density. Low density antigens need bright fluorophores on clean detectors; high density lineage markers can sit anywhere. Getting this backwards is why panels underperform their design.
5. Check the epitope survives your processing. Enzymatic dissociation cleaves several surface antigens, and fixation destroys others. Where a marker matters, confirm with an alternative clone or a gentler protocol.

The clone is the reagent

Cluster designations were created so that reagents could be compared, and they succeeded well enough that people now treat the designation as the specification. It is not: the clone, its host, its fluorophore and its lot are the specification.

Record all four in the protocol. It is what lets a panel be rebuilt in another laboratory and what makes a discrepancy investigable.

Blocking is not optional

Fc receptor mediated binding affects exactly the populations most often studied, and it produces a plausible looking positive signal rather than obvious noise. That is what makes it dangerous.

Include the block in the standard protocol rather than as an option for difficult samples, and include an unstained and a fully blocked control when a new sample type is introduced.

A cd80 antibody beside its partner receptor

CD80 and CD86 both engage the same costimulatory receptors with different kinetics, so a cd80 antibody is read beside its partner rather than alone, and both rise on activation from a low resting level. Blocking experiments need a functional grade clone with an isotype control, which is a separate validation from detection. Surface levels are modest, so conjugate brightness matters.

A cd200 antibody and an inhibitory signal

CD200 delivers an inhibitory signal to myeloid cells through its own receptor, so a cd200 antibody is read with that receptor stained on the other population, since the pair is the mechanism. Expression is broad and graded, which means the gate is set against an internal negative in the same sample. A blocking clone is a different product from a staining one.

A cd49d antibody and an integrin subunit

CD49d is the alpha 4 integrin subunit, which pairs with two different beta chains to make receptors with different ligands, so a cd49d antibody reports the subunit rather than a functional receptor and the partner chain belongs in the panel. The integrin changes conformation on activation and some clones are conformation dependent, which is useful or confounding by design.

A cd61 antibody and the platelet integrin

CD61 is the beta 3 integrin subunit found on platelets and megakaryocytes, so a cd61 antibody marks that lineage and is read with its alpha partner. Platelets activate during handling, which changes both the level and the conformation, so anticoagulant choice and time to analysis are part of the measurement rather than details of the protocol.

A cd26 antibody and an enzyme on the surface

CD26 is dipeptidyl peptidase 4, so a cd26 antibody reports a protein that is both a marker and an enzyme, and antigen and activity are different measurements. Some clones inhibit the enzyme, which matters for functional work and should be stated. It is shed into plasma, so an extracellular domain reagent will also detect the soluble form.

A gprc5d antibody and a surface target for therapy

A gprc5d antibody reports a receptor expressed on plasma cells and little else, which is why it has become a target for engineered therapies, and detecting it is hard because expression is low and the extracellular region is short. A clone validated on a transfected control and on primary cells is the only usable kind.

An s1pr1 antibody and a receptor that moves

An s1pr1 antibody reports a lipid receptor whose surface level changes within minutes of exposure to its ligand, so a staining result is a snapshot of a dynamic equilibrium rather than an expression level. Fixation timing therefore changes the answer, which is why a protocol states it precisely.

Common questions

Why is everything positive in my myeloid stain despite a good CD32 antibody?

Almost certainly unblocked Fc receptors. Add an appropriate blocking step before the panel and the background usually disappears entirely.

Are two clones against the same marker interchangeable?

No. They recognise different epitopes with different sensitivity to fixation and dissociation, and they frequently stain different fractions. Treat a clone change as a protocol change.

Should I use the datasheet dilution?

As a starting point only. Titration on your own cells almost always improves separation, and it is one plate of work per clone.

Browse by service class

• Compare Gene synthesis on advertised prices